DURAVYU (EYP-1901) - (LUGANO)

September 2, 2026: EyePoint, Inc. (NASDAQ: EYPT) announced upcoming investor conference participation and scientific presentations on EYP-1901/DURAVYU (vorolanib intravitreal insert), an investigational sustained-release treatment for retinal disease.

Investor events: fireside chats at the Citi 2026 Biopharma Back to School Conference on September 9, 2026; Cantor Global Healthcare Conference 2026 on September 10, 2026; and Morgan Stanley Global Healthcare Conference on September 15, 2026.

Scientific catalyst: at The Retina Society 59th Annual Scientific Meeting in Los Angeles (September 23-26, 2026), the company will present on September 24 first-time LUGANO Phase 3 trial outcomes for EYP-1901 versus aflibercept in neovascular age-related macular degeneration (nAMD), including vision and anatomic outcomes, plus separate first-time safety and treatment-burden outcomes. A separate presentation will cover EYP-1901’s mechanism of action and pharmacokinetic characteristics in retinal exudative disease. On September 25, an IRIS Registry analysis will examine central subfield thickness fluctuation and visual acuity outcomes in nAMD.

The company states DURAVYU has been conditionally accepted by FDA as the proprietary name for EYP-1901 and remains investigational, with Phase 3 pivotal trials ongoing in wet AMD and diabetic macular edema.